Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
VLX-1005 by Veralox Therapeutics for Heparin-Induced Thrombocytopenia: Likelihood of Approval
VLX-1005 is under clinical development by Veralox Therapeutics and currently in Phase II for Heparin-Induced Thrombocytopenia. According to GlobalData, Phase...